Rozanolixizumab prevents congenital heart block in high-risk pregnancy

Congenital heart block, sometimes referred to as cardiac neonatal lupus, is a rare but potentially life-threatening condition that affects babies born to mothers with specific autoantibodies – called anti-SSA/Ro antibodies – which can attack the fetal heart via its electrical conduction system, leading to a slower heart rate.